Neoprobe works toward FDA approval of anti-cancer agent RIGScan

10/22/2010 |

Neoprobe plans to submit to the FDA a biologic-license application for RIGScan, a cancer-targeting drug. The move is among the agency's prerequisites to conduct clinical studies. The company is also looking to file an investigational new-drug application for the agent later.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX